Aryx Therapeutics, Inc.

Renexxion, LLC

Xyra, LLC

Altos Therapeutics, LLC

Advanced Therapies, Inc.

Armetheon, Inc.

Millennium Pharmaceuticals Limited

Pascal Jean Druzgala

Peter G Milner

Cyrus K Becker

Xiaoming Zhang

Jurg R Pfister

Peter Gerard Milner

Monica H Palme

Jien Heh Tien

Ian Irwin

Peter Milner

Gary W Luehr

Jürg Roland Pfister

Priyadarshini Jaishankar

Philip W Payne

Arathi Sundaram

J&uuml;rg Pfister

Courtney Rubens

Jason P Adams

Jien-Heh J Tien

Arthur John Cooper

Jurg R Pfiste

Art Cooper

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

Pharmaceutical formulations and methods for the treatment of gastrointestinal disorders

Disclosed are cardioversion methods for patients with either paroxysmal or persistent AFib which methods use budiodarone or a pharmaceutical composition comprising budiodarone.

Cardioversion methods using budiodarone

Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and/or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and/or congestive heart failure in the treated patient.

Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations

Pharmaceutical formulations for the treatment of gastrointestinal disorders

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3&#x2032;-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

Methods for the treatment of gastro-intestinal disorders

Material for the treatment of gastro-intestinal disorders

Material and methods for the treatment of gastro-intestinal disorders

Provided are Dor Dantagonist compounds and pharmaceutical compositions of formula I and pharmaceutically acceptable salts thereof, or isomers thereof, wherein R, Rand Rare as defined herein. The invention further comprises methods for making the compounds of the invention and methods for the treatment of conditions mediated by the dopamine Dor Dreceptor from the compounds of the invention.

[object Object]

The subject invention provides stereoisomeric compounds of formula (X): 

Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders

Growing community of inventors

Santa Rosa, CA, United States of America

Pascal Jean Druzgala